In 2016, the U.S. Preventive Services Task Force (USPSTF) released new recommendations supporting the use of low-dose aspirin for the primary prevention of CRC and cardiovascular disease (CVD) in adults aged 50-59 with ≥10% 10-year CVD risk. However, there remain many critical knowledge gaps regarding its mechanisms and effectiveness in preventing other cancers and cancer mortality. Dr. Cao is leading interdisciplinary research to:
- Estimate the association between long-term aspirin use and mortality
- Refine the current USPSTF guidelines taking into account underlying CRC risk
- Assess the impact and challenges in implementation
These efforts will inform future innovative multi-level interventions to improve the implementation of precision aspirin primary prevention strategies across systems, providers, and patients.